Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production

摘要

Described herein are vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminus heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.